NCT06826989View on ClinicalTrials.gov

A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

March 19, 2025

Primary Completion Date

June 4, 2025

Study Completion Date

June 4, 2025

Conditions

Healthy

Interventions

DRUG

[14C]MK-8527

Oral Dose

Trial Locations (1)

53704

Fortea CRU Madison ( 0001), Madison

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY